Navigation Links
Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
Date:6/9/2009

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of Parkinson's disease therapies will increase modestly from $2.5 billion in 2008 to $2.8 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the dopamine agonist drug class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab and UCB/Schwarz Pharma's Neupro. However, sales of some of these agents, including Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab, will be offset by increased uptake of generic equivalents. Market growth will also be constrained by the generic erosion of other key therapies, including Novartis/Orion Pharma's Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck's Agilect/Azilect.

According to the report, market sales will also be driven by the emergence of novel agents, most notably Merck Serono/EMD Serono/Newron Pharmaceuticals' safinamide, Solvay Pharmaceuticals' pardoprunox, and Acadia Pharmaceuticals/Biovail Pharmaceuticals' pimavanserin, which will be used to treat niche Parkinson's disease populations.

The report also finds that the results of recent key clinical trials will affect the way clinicians treat patients with early Parkinson's disease.

"The results of the ADAGIO trial demonstrated the disease-modifying effects of Agilect/Azilect, making it more likely that physicians will prescribe this drug to newly-diagnosed Parkinson's disease patients," said Decision Resources Analyst Sami Fam, Ph.D. "However, the need for a more definitive and robust neuroprotective therapy remains in the indication, and this unmet need is not expected to be fulfilled over the next ten years."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. High pollution linked to poor lung function growth in children in Mexico City
2. Researchers develop long-lasting growth hormone
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
5. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
6. AWT Management Announce Aggressive Growth and Acquisition Strategy
7. Cynosure to Present at the Maxim Group Growth Conference
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
10. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology: